US EditionNeurizon makes appointments to executive team - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Neurizon makes appointments to executive team - Pharmafile
Neurizon Therapeutics, a clinical-stage biotech company focusing on treatments for neurodegenerative diseases, has announced three leadership appointments. These will support the company’s ambition to commercialise its leading therapy NUZ-001, a treatment for Amyotrophic lateral sclerosis (ALS) motor neurone disease. Kathryn Williams joins as chief regulatory officer (CRO). She brings over two decades of global regulatory […] The post Neurizon m…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
